U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07227636) titled 'A Study of Botensilimab and Balstilimab for Colorectal Cancer' on Nov. 10.
Brief Summary: The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colon cancer or colorectal liver metastases (CRLM) who have measurable residual disease (MRD) after standard treatment with surgery and chemotherapy.
Study Start Date: Nov. 07
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer
Intervention:
DRUG: Botensilimab
All patients will receive botensilimab IV on day 1 of the 42 ...